Persistent endotheliopathy in the pathogenesis of long COVID syndrome: Comment from von Meijenfeldt et al.
作者信息
von Meijenfeldt Fien A, Havervall Sebastian, Adelmeijer Jelle, Thalin Charlotte, Lisman Ton
机构信息
Surgical Research Laboratory, Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
Division of Internal Medicine, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.
出版信息
J Thromb Haemost. 2022 Jan;20(1):267-269. doi: 10.1111/jth.15580. Epub 2021 Nov 22.
Abstract
摘要
相似文献
1
Persistent endotheliopathy in the pathogenesis of long COVID syndrome: Comment from von Meijenfeldt et al.长期新冠综合征发病机制中的持续性内皮病变：冯·梅延费尔特等人的评论
J Thromb Haemost. 2022 Jan;20(1):267-269. doi: 10.1111/jth.15580. Epub 2021 Nov 22.
2
Persistent endotheliopathy in the pathogenesis of long COVID syndrome - Reply to comment from von Meijenfeldt et al.长新冠综合征发病机制中的持续性内皮病变——对冯·梅延费尔特等人评论的回复
J Thromb Haemost. 2022 Jan;20(1):270-271. doi: 10.1111/jth.15578. Epub 2021 Nov 22.
3
Persistent endotheliopathy in the pathogenesis of long COVID syndrome.长新冠综合征发病机制中的持续内皮病变。
J Thromb Haemost. 2021 Oct;19(10):2546-2553. doi: 10.1111/jth.15490. Epub 2021 Sep 12.
4
Sustained VWF-ADAMTS-13 axis imbalance and endotheliopathy in long COVID syndrome is related to immune dysfunction.在长新冠综合征中，持续的 VWF-ADAMTS-13 轴失衡和血管内皮病变与免疫功能障碍有关。
J Thromb Haemost. 2022 Oct;20(10):2429-2438. doi: 10.1111/jth.15830. Epub 2022 Aug 4.
5
COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects.新冠病毒病是一种系统性血管血液病：对发病机制及临床方面的见解
Angiogenesis. 2021 Nov;24(4):755-788. doi: 10.1007/s10456-021-09805-6. Epub 2021 Jun 28.
6
COVID-19: Evaluation and Care of Patients With Persistent Symptoms Following Acute SARS-CoV-2 Infection.COVID-19：急性 SARS-CoV-2 感染后持续症状患者的评估和护理。
Ann Intern Med. 2021 Aug;174(8):1159-1160. doi: 10.7326/M21-2342. Epub 2021 Jun 11.
7
Early clues regarding the pathogenesis of long-COVID.长新冠发病机制的早期线索。
Trends Immunol. 2022 Apr;43(4):268-270. doi: 10.1016/j.it.2022.02.008. Epub 2022 Mar 8.
8
COVID fog demystified.新冠迷雾消散。
Cell. 2022 Jul 7;185(14):2391-2393. doi: 10.1016/j.cell.2022.06.020. Epub 2022 Jun 15.
9
The coagulopathy, endotheliopathy, and vasculitis of COVID-19.COVID-19 的凝血功能障碍、血管内皮功能障碍和血管炎。
Inflamm Res. 2020 Dec;69(12):1181-1189. doi: 10.1007/s00011-020-01401-6. Epub 2020 Sep 12.
10
Return-to-work, disabilities and occupational health in the age of COVID-19.新冠疫情时代的重返工作岗位、残疾与职业健康。
Scand J Work Environ Health. 2021 Jul 1;47(5):408-409. doi: 10.5271/sjweh.3960. Epub 2021 May 18.
引用本文的文献
1
Quality of life and ability to work of patients with Post-COVID syndrome in relation to the number of existing symptoms and the duration since infection up to 12 months: a cross-sectional study.新冠后综合征患者的生活质量和工作能力与现有症状数量及感染后至 12 个月的持续时间的关系：一项横断面研究。
Qual Life Res. 2023 Jul;32(7):1991-2002. doi: 10.1007/s11136-023-03369-2. Epub 2023 Mar 3.
2
Neurobiology of long-COVID: Hypotheses and unanswered questions.长新冠的神经生物学：假说与未解之谜
Anaesth Crit Care Pain Med. 2023 Jun;42(3):101201. doi: 10.1016/j.accpm.2023.101201. Epub 2023 Feb 15.
3
Commentary on "The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1".关于“COVID-19中纤溶反应欠佳由高纤溶酶原激活物抑制剂-1所致”的评论
J Thromb Haemost. 2022 Oct;20(10):2211-2213. doi: 10.1111/jth.15839.
4
The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1.COVID-19 中纤溶反应不佳是由高水平 PAI-1 决定的。
J Thromb Haemost. 2022 Oct;20(10):2394-2406. doi: 10.1111/jth.15806. Epub 2022 Jul 21.
5
Protection by metformin against severe Covid-19: An in-depth mechanistic analysis.二甲双胍对严重 COVID-19 的保护作用：深入的机制分析。
Diabetes Metab. 2022 Jul;48(4):101359. doi: 10.1016/j.diabet.2022.101359. Epub 2022 May 31.
6
Impaired exercise capacity in post-COVID-19 syndrome: the role of VWF-ADAMTS13 axis.新冠后综合征中运动能力受损：vWF-ADAMTS13 轴的作用。
Blood Adv. 2022 Jul 12;6(13):4041-4048. doi: 10.1182/bloodadvances.2021006944.
7
Persistent endotheliopathy in the pathogenesis of long COVID syndrome - Reply to comment from von Meijenfeldt et al.长新冠综合征发病机制中的持续性内皮病变——对冯·梅延费尔特等人评论的回复
J Thromb Haemost. 2022 Jan;20(1):270-271. doi: 10.1111/jth.15578. Epub 2021 Nov 22.
本文引用的文献
1
Hemostasis and fibrinolysis in COVID-19 survivors 6 months after intensive care unit discharge.新冠重症监护病房出院6个月后康复者的止血与纤溶情况
Res Pract Thromb Haemost. 2021 Sep 24;5(6):e12579. doi: 10.1002/rth2.12579. eCollection 2021 Aug.
2
Persistent endotheliopathy in the pathogenesis of long COVID syndrome.长新冠综合征发病机制中的持续内皮病变。
J Thromb Haemost. 2021 Oct;19(10):2546-2553. doi: 10.1111/jth.15490. Epub 2021 Sep 12.
3
Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge.新冠病毒感染患者出院4个月后持续存在血栓前状态改变。
Blood Adv. 2021 Feb 9;5(3):756-759. doi: 10.1182/bloodadvances.2020003968.
4
Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality.新冠肺炎患者的血栓前状态改变与疾病严重程度和死亡率相关。
Res Pract Thromb Haemost. 2020 Dec 6;5(1):132-141. doi: 10.1002/rth2.12462. eCollection 2021 Jan.
5
Increased plasminogen activator inhibitor results in a hypofibrinolytic state in adolescents with obesity: in vivo and ex vivo evidence.纤溶酶原激活物抑制剂增加导致肥胖青少年纤溶状态低下：体内和体外证据
Br J Haematol. 2016 Oct;175(2):300-307. doi: 10.1111/bjh.14238. Epub 2016 Jul 19.
Zotero 插件